StockMarketWire.com - Summit Therapeutics said it had discovered a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action.

In early testing, the compounds were shown to have high potency against strains of gonorrhoea with no development of resistance to date.

The series of antibiotic compounds was identified using Summit's recently-acquired technology platform.

'Summit intends to select a candidate from the gonorrhoea programme for entering into IND enabling studies in the second half of 2018,' it said.

'The company believes the identified series of antibiotic compounds has the potential to produce a new front-line therapy for gonorrhoea.'


At 1:45pm: [LON:SUMM] Summit Therapeutics PLC share price was +7.5p at 195p



Story provided by StockMarketWire.com